No. The surgical complete responses are not recorded as part of the complete responses in the Phase II trial. These are part of the extension trial. The results appear to be significant, given that the only 2 patients that have completed the extension study have been able to have the remaining tumours removed. There are another 3 currently in the extension trial, hopefully they have a similar outcome.
This information has been reported in the recent media releases.
- Forums
- ASX - By Stock
- VLA
- we value viralytics at a$0.69/share
we value viralytics at a$0.69/share, page-22
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online